$PEAR News

Last published 3y ago

3y agoPEARPear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales ProcessBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR) ("the Company"), a company focused on developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that the Company and
3y agoGLS PEAR SGHTSight Sciences Appoints Ali Bauerlein as Chief Financial OfficerGlobeNewswireMENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to
3y agoCDTX ELVN IMPL PEAR+55AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough ScienceGlobeNewswireSAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia
3y agoPEARPear Therapeutics Announces Process Exploring Strategic AlternativesBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR) ("the Company"), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it is engaged in a
3y agoPEARPear Therapeutics to Participate in 43rd Annual Cowen Healthcare ConferenceBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate in the 43rd
3y agoPEARPear Therapeutics to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate in the BTIG
3y agoPEARPear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use DisordersBusiness WireBrightView expands its initiative with reSET® and reSET-O® to patients across Kentucky, Ohio, Delaware, Massachusetts, and Virginia Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and
3y agoPEARPear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug ListBusiness WirePear's prescription digital therapeutics (PDTs), reSET® and reSET-O®, are included on the January 2023 Florida Medicaid Preferred Drug List (PDL), effective January 1, 2023 Florida Medicaid is covering
3y agoPEARPear Therapeutics to Participate in Citi's BioTech C-Suite Virtual Fireside Chat SeriesBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in Citi's
3y agoPEARCalifornia Department of Health Care Services Awards Contract to Pear Therapeutics to Support the Recovery Incentives ProgramBusiness WireThe California Department of Health Care Services (DHCS) selected Pear Therapeutics to track and distribute incentives for the groundbreaking Recovery Incentives: California's Contingency Management Program, to treat
3y agoPEARPear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital TherapeuticsBusiness WireCOEUS' COEBRA™ Platform to Facilitate Value and Outcomes Based Agreements for Government and Commercial Payers Pear Therapeutics, Inc. (NASDAQ:PEAR) ("Pear"), the leader in developing and commercializing
3y agoPEARPear Therapeutics and Spero Health to Expand Access to Prescription Digital Therapeutics for People in Recovery Across Multiple Locations and StatesBusiness WireSpero Health, one of the nation's largest office-based outpatient opioid treatment providers for individuals in recovery, to expand patient access to Pear's prescription digital therapeutics (PDTs) for the treatment of
3y agoPEARPear Therapeutics Presents Real-World Clinical Data Assessing Engagement and Abstinence in Patients with Alcohol Use Disorders Using reSET® at AAAPBusiness WireAlcohol is the most common substance use disorder (SUD), representing 70% of the more than 40 million people with SUD1 New data from real-world use of reSET® demonstrate patients who use alcohol exhibit robust
3y agoPEARPear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx ConferenceBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Evercore
3y agoPEARPear Therapeutics Reports Third Quarter 2022 ResultsBusiness WireGrew revenue 24% quarter-over-quarter to $4.1 million Expanded patient access with new state and commercial payors Expanded real-world evidence with new peer reviewed publication Reduced quarter-over-quarter
4y agoPEARPear Therapeutics to Participate in the BTIG Digital Health ForumBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced management's participation in the virtual
4y agoPEARPear Therapeutics Presents Real-World Data Showing Reduction in Healthcare Resource Utilization and Associated Costs in Adults Using Somryst® at ISPOR EuropeBusiness WireSomryst® is the only FDA-authorized prescription digital therapeutic (PDT) for the treatment of chronic insomnia Analysis demonstrated potential per-patient cost reductions over 24 months of $8,202 compared to
4y agoPEARState of Wisconsin to Provide Access to Prescription Digital Therapeutics to Help Local Communities Fight Against Addiction CrisisBusiness WireThe Wisconsin Department of Health Services awards Pear funding towards access to Pear's reSET® and reSET-O® to patients with substance use disorder and opioid use disorder The program will support
4y agoPEARPear Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare ConferenceBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Credit
4y agoPEARPear Therapeutics to Issue Third Quarter 2022 Financial Results on Monday, November 14, 2022Business WirePear Therapeutics, Inc. (the "Company") (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its third
4y agoPEARPear Therapeutics Announces Publication of Real-World Data Showing High Rates of Engagement, Retention and Abstinence with reSET®Business WireReal-world observational analysis evaluating treatment of substance use disorder (SUD) with prescription digital therapeutics (PDTs) among a large, geographically diverse population Results demonstrate the benefit of
4y agoPEARPear Therapeutics to Participate in LifeSci Partners HealthTech SymposiumBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the LifeSci Partners HealthTech Symposium on Se
4y agoPEARPear Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare ConferenceBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Morgan Stanley 20th Annual Global Healthcar
4y agoPEARSouth Carolina Department of Corrections and Pear Therapeutics Team up to Support Inmates in Recovery from Substance Use DisordersBusiness WireCamille Griffin Graham Correctional Institution, a state prison for women in Columbia, S.C., is the first in the nation to implement FDA-authorized PDTs in a correctional setting Collaboration delivers Pear's reSET® and reSET-O®, for treatmen
4y agoPEARPear Therapeutics to Participate in Citi's 17th Annual BioPharma ConferenceBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in Citi's 17th Annual BioPharma Conference taking
4y agoPEARPear Therapeutics Reports Second Quarter 2022 ResultsBusiness Wire20% quarter-over-quarter revenue growth to $3.3 million Recent real-world health economic data for all three of Pear's commercial products show cost-savings1-3 Recent commercial formulary additions for reSET® and reSET-O® Pear Therapeut
4y agoPEARPear Therapeutics Announces Publication of New Analysis of Real-World Data Showing Reduction in Insomnia Severity, Healthcare Resource Utilization and Associated Costs in Adults Using Somryst®Business WireSomryst® is the only FDA-authorized prescription digital therapeutic (PDT) for the treatment of chronic insomnia 24-month analysis showing $2,059 reduction in per-patient costs adds to the body of evidence to support the use of this PDT among peo
4y agoPEARPear Therapeutics and SelectHealth Announce Coverage to Provide Access to FDA-Authorized Prescription Digital Therapeutic for the Treatment of Opioid Use DisorderBusiness WireSelectHealth teams with Pear to provide its members with covered access to Pear's innovative prescription digital therapeutic (PDT), reSET-O®, for the treatment of opioid use disorder (OUD) as adjunct to outpatient treatment that includes transmucosa
4y agoPEARPear Therapeutics and Cove Behavioral Health to Provide Patients Access to Prescription Digital Therapeutic for the Treatment of Opioid Use DisorderBusiness WireCove Behavioral Health will provide access to Pear's reSET-O® to patients with opioid use disorder through a State Opioid Response (SOR) grant Cove, which serves over 30,000 individuals in the Tampa Bay community each year, will offer Pear's r
4y agoPEARPear Therapeutics to be Added to Russell US Index SeriesBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today that it will be added to the Russell US Index Series in conjunction with the Se
4y agoPEARPear Therapeutics to Issue Second Quarter 2022 Financial Results on Thursday, August 11, 2022Business WirePear Therapeutics, Inc. (the "Company") (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its second quarter 2022 financial results after t
4y agoPEARPear Therapeutics to Participate in the Cowen 7th Annual FutureHealth ConferenceBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in Cowen's 7th Annual FutureHealth Conference, a v
4y agoPEARPear Therapeutics Announces Three New Board MembersBusiness WireNew Board Members Paul Mango, Shiva Rajaraman, and Tim Wicks bring a depth of experience and knowledge in both the healthcare and technology industries Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-b
4y agoPEARPear Therapeutics Announces New 12-Month Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Treated with reSET-O®Business WirereSET-O® is the only FDA-authorized prescription digital therapeutic (PDT) for the treatment of opioid use disorder (OUD) Results support the real-world value of reSET-O, demonstrating durable treatment outcomes and reductions in healthcare resou
4y agoPEARPear Presents Interim Real-World Data Showing Significant Reductions in Symptoms of Chronic Insomnia, Anxiety and Depression with Somryst® at SLEEP 2022Business WireInterim results from the DREAM trial showed treatment with Somryst, a prescription digital therapeutic (PDT) for patients with chronic insomnia, achieved significant reductions in symptoms of insomnia, anxiety and depression severity through six month
4y agoPEARPear Therapeutics Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET® at Six MonthsBusiness WirereSET® is the only FDA-authorized prescription digital therapeutic (PDT) for the treatment of substance use disorder (SUD), including alcohol, cannabis, cocaine, and stimulants Results support the real-world value of reSET, demonstrating durab
4y agoPEARPear Therapeutics to Participate in the Jefferies Healthcare ConferenceBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Jefferies Healthcare Conference taking plac
4y agoPEARPear Announces Health Equity Data Showing Similar Engagement with reSET-O® Across US Geographic Regions Presented at APA Annual MeetingBusiness WireResults demonstrate that reSET-O®, the only FDA-authorized prescription digital therapeutic (PDT) for the treatment of opioid use disorder (OUD), reached patients across a broad range of geographies, from urban to rural1 Results suggest PDTs may
4y agoPEARPear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022Business WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it will host an inaugural virtual Investor Day on June 6, 2022, at 10:00 a
4y agoPEARPear Therapeutics Reports First Quarter 2022 Financial ResultsBusiness Wire108% quarter-over-quarter revenue growth to $2.7 million >9,200 total prescriptions in the first quarter for Pear's three FDA-authorized products Expanded patient access with state payors in Michigan and Oklahoma CMS issued new HCPCS code
4y agoPEARPear Therapeutics Announces the Inclusion of QuickMD in Its Telehealth Provider Experience InitiativeBusiness WirePear's second telehealth offering for reSET-O® is with QuickMD, a telemedicine platform providing consultations and urgent care Pear is working with QuickMD to assist eligible patients in their recovery from opioid use disorder Pear Therapeu
4y agoPEARPear Therapeutics to Participate in the 17th Annual Needham Technology & Media ConferenceBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the 17th Annual Needham Technology & Media Conf
4y agoPEARPear Therapeutics to Participate in the Bank of America 2022 Healthcare ConferenceBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Bank of America 2022 Healthcare Conference
4y agoPEARPear Therapeutics to Issue First Quarter 2022 Financial Results on Monday, May 16, 2022Business WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that the company will issue its first quarter 2022 financial results after the
4y agoPEARPear Therapeutics to Present at 2022 Rx and Illicit Drug SummitBusiness WirePear to host panel discussion with leaders who are paving the way to provide patients access to prescription digital therapeutics for the treatment of substance use and opioid use disorders Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in develop
4y agoPEARPear Therapeutics Receives Safer Technologies Program (STeP) Designation from FDA for Product Candidate to Treat Acute and Chronic PainBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it has received Safer Technologies Program (STeP) for Medical Devices designati
4y agoCAH MRNA PEAR XRAY+1Jorge Gomez Joins Moderna as Chief Financial OfficerACCESS NewswireCAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday,
4y agoPEARPear Therapeutics to Participate in Upcoming Investor ConferencesBusiness WirePear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today announced management will participate in the following upcoming virtual investor confere
4y agoPEARPear Therapeutics Announces Program to Bring Prescription Digital Therapeutics to Patients in Recovery Through a Telehealth Provider ExperienceBusiness WirePear is working with select telehealth providers to put recovery in the hands of those seeking help remotely Pear's first telehealth offering is with PursueCare, a leading telehealth addiction treatment provider, to offer patients an end-to-end
4y agoPEARPear Therapeutics Reports Fourth Quarter and Full Year 2021 Financial ResultsBusiness Wire$4.2 million total revenue for the full year 2021 2021 highlights include Current Procedural Terminology (CPT) codes for prescribers, first state Medicaid coverage decision, two major PBM formulary additions, more than 30 organizations providin